D G Knapen - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Practical Laboratory Medicine|September 1, 2017

False positive acetaminophen concentrations in icteric serumL de Jong, D G Knapen, T H Oude Munnink, et al.

ESMO Real World Data and Digital Oncology|April 3, 2026

Artificial intelligence for clinical trial design, conduct, and analysis: a narrative reviewD G Knapen, M van Kruchten, D J A de Groot, et al.

Virchows Archiv : an International Journal of Pathology|September 19, 2025

Metastatic mismatch repair deficient oesophageal squamous cell carcinoma leading to diagnosis of Lynch syndrome with a complete response to nivolumab treatmentH H Wang, G Kats-Ugurlu, R H Sijmons, et al.

ESMO Open|November 21, 2025

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumorsA Minchom, O Lindén, D G Knapen, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Practical Laboratory Medicine|September 1, 2017

False positive acetaminophen concentrations in icteric serumL de Jong, D G Knapen, T H Oude Munnink, et al.

ESMO Real World Data and Digital Oncology|April 3, 2026

Artificial intelligence for clinical trial design, conduct, and analysis: a narrative reviewD G Knapen, M van Kruchten, D J A de Groot, et al.

Virchows Archiv : an International Journal of Pathology|September 19, 2025

Metastatic mismatch repair deficient oesophageal squamous cell carcinoma leading to diagnosis of Lynch syndrome with a complete response to nivolumab treatmentH H Wang, G Kats-Ugurlu, R H Sijmons, et al.

ESMO Open|November 21, 2025

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumorsA Minchom, O Lindén, D G Knapen, et al.

Pageof 1